SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives
SGLT2 inhibitors and exercise target kidney disease through overlapping biological pathways, but stronger clinical evidence is needed to confirm the combined approach excels.
This review synthesizes the mechanistic rationale for combining SGLT2 inhibitors with structured exercise in diabetic kidney disease, identifying convergent effects on glomerular hemodynamics, oxidative stress, and renal fibrosis pathways. Despite compelling biological plausibility, direct clinical evidence supporting superiority of the combined approach over individual interventions is lacking, and the review outlines a research agenda for adequately powered RCTs.
What the study was
- Study design
- Narrative review
- Category
- T7: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
- Maturity
- Exploratory
- Journal
- Frontiers in Medicine
Why it surfaced
Addresses combination therapy optimization for DKD using SGLT2 inhibitors—a direct watchlist target—with mechanistic depth and clear clinical research gaps relevant to precision cardiorenal risk management.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.